Announcements Trials
Browse Landscape

Status

Completed 3Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 40Observational 5Expanded_access 2

Sponsor

Cancer Type

Thoracic 4Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 1ALK-positive NSCLC 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Observational × ceritinib × Clear all
NCT05834348 2025-03-30

DELINOR

Pfizer

Completed
5,279 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Takeda

Completed
111 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Shandong University

Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Sungkyunkwan University

Unknown
4,724 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡